Form 4 for CHRS Coherus Oncology, Inc.

Accepted 2021-07-08 00:00:00 ET · period of report 2021-07-06 · accession 0001567619-21-013149 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2021-07-08	2021-07-06	CHRS	Anicetti Vincent R	COO	A - Grant	$0.00	+50.0K	124.8K	+67%	$0
D	2021-07-08	2021-07-06	CHRS	Anicetti Vincent R	COO	A - Grant	$0.00	+150.0K	150.0K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-07-06	A	A	50,000	$0.00	124,790	D	—	—	(F1) Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/2 of the RSUs vest annually on July 6 of each year, with the first 1/2 vesting on July 6, 2022 and with the RSUs being fully vested on July 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. (F2) Includes 122,083 RSUs and 1,388 shares of Common Stock purchased under Issuer's Employee Stock Purchase Plan on May 14, 2021 in a transaction exempt from Section 16(b) under Rule 16b3(c).
2	Derivative	Stock Option (Right to Buy)	2021-07-06	A	A	150,000	$0.00	150,000	D	$13.63 · — to 2031-07-06	150,000 Common Stock	(F3) The underlying shares subject to the option vest and become exercisable as to 1/24th of the total number of shares subject to the option in successive, equal monthly installments measured from July 6, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.